Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.

BACKGROUND The tumor immune microenvironment (TIME) of lung cancer brain metastasis is largely unexplored. We performed immune profiling and sequencing analysis of paired resected primary tumors and brain metastases of non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS TIME profiling of archival formalin-fixed and paraffin embedded specimens of paired primary tumors and brain metastases from 39 patients with surgically resected NSCLCs was performed using a 770 immune gene expression panel and by T cell receptor beta repertoire (TCRß) sequencing. Immunohistochemistry was performed for validation. Targeted sequencing was performed to catalog hot spot mutations in cancer genes. RESULTS Somatic hot spot mutations were mostly shared between both tumor sites (28/39 patients; 71%). We identified 161 differentially expressed genes, indicating inhibition of dendritic cell maturation, Th1, and leukocyte extravasation signaling pathways, in brain metastases compared to primary tumors (p < 0.01). The proinflammatory cell adhesion molecule vascular cell adhesion protein 1 was significantly suppressed in brain metastases compared to primary tumors. Brain metastases exhibited lower T cell and elevated macrophage infiltration compared with primary tumors (p < 0.001). T cell clones were expanded in 64% of brain metastases compared with their corresponding primary tumors. Further, while TCR repertoires were largely shared between paired brain metastases and primary tumors, T cell densities were sparse in the metastases. CONCLUSION We present findings that suggest that the TIME in brain metastases from NSCLC is immunosuppressed and comprises immune phenotypes (e.g. immunosuppressive tumor-associated macrophages) that may help guide immunotherapeutic strategies for NSCLC brain metastases.

[1]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[2]  M. Ernst,et al.  Targeting Macrophages in Cancer: From Bench to Bedside , 2018, Front. Oncol..

[3]  Asha A. Nair,et al.  Contraction of T cell richness in lung cancer brain metastases , 2018, Scientific Reports.

[4]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[5]  H. Iwata,et al.  Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer , 2017, Oncotarget.

[6]  F. Aversa,et al.  Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value , 2017, Clinical Cancer Research.

[7]  S. Lucas,et al.  Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies , 2017, Front. Immunol..

[8]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[9]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[10]  Zhihong Chen,et al.  Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. , 2017, Cancer research.

[11]  D. Quail,et al.  The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.

[12]  C. Brennan,et al.  Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. , 2016, Cell reports.

[13]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet Oncology.

[14]  S. Hanash,et al.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. , 2016, Cancer research.

[15]  Jonathan Kipnis,et al.  Revisiting the Mechanisms of CNS Immune Privilege. , 2015, Trends in immunology.

[16]  Michael Detmar,et al.  A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules , 2015 .

[17]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[18]  P. Ellis,et al.  Brain metastases in non-small-cell lung cancer. , 2014, Clinical lung cancer.

[19]  D. Wong,et al.  Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis , 2014, BMC Urology.

[20]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[21]  H. Kettenmann,et al.  The brain tumor microenvironment , 2011, Glia.

[22]  E. Pamer,et al.  Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.

[23]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[24]  D. Hollis,et al.  Factors associated with the development of brain metastases , 2010, Cancer.

[25]  C. Hunter,et al.  Trafficking of immune cells in the central nervous system. , 2010, The Journal of clinical investigation.

[26]  F. de Marinis,et al.  Multimodality management of non-small cell lung cancer patients with brain metastases , 2010, Current opinion in oncology.

[27]  K. Pienta,et al.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.

[28]  S. Lehnardt,et al.  Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll‐like receptor‐mediated neuronal injury , 2009, Glia.

[29]  Massimo Cristofanilli,et al.  A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. , 2009, The Journal of surgical research.

[30]  R. Figlin,et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.

[31]  L. Carey,et al.  Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[33]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[34]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[36]  B. Scheithauer,et al.  Microglia in brain tumors , 2002, Glia.

[37]  A. Young,et al.  Treatment for patients with cerebral metastases. , 1978, Archives of neurology.

[38]  A. Fauci,et al.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations. , 1976, Annals of internal medicine.